Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis

doi:10.1016/S0002-9149(99)80686-9

The American Journal of Cardiology

Volume 75, Issue 14, 1 May 1995, Pages 913-918

https://doi.org/10.1016/S0002-9149(99)80686-9 Get rights and content

Circulating levels of extracellular matrix components were measured by radioimmunoassays and tested if they were useful for clinical staging in chronic heart failure. In 41 patients with dilated cardiomyopathy (33 idiopathic and 8 ischemic cases), the serum concentrations of procollagen type III aminoterminal peptide (PIIINP), type I collagen telopeptide (ICTP), and basement membrane laminin were significantly higher than in 30 healthy controls regardless of the underlying etiology. Patients with serum values of PIIINP, ICTP, and laminin >7 μg/L, 7.6 μg/L, and 2.3 U/ml, respectively, were at higher relative risk for advanced clinical stage, poor hemodynamic condition, hyponatremia, heart transplantation, and death during follow-up than patients with low levels, with the exception that serum laminin >2.3 U/ml was not significantly associated with hyponatremia and heart transplantation. Despite their interdependence on liver function, circulating levels of PIIINP and ICTP were independent predictors of mortality. In 17 of the 41 patients with cardiomyopathy whose explanted hearts were available for histologic evaluation, serum PIIINP, ICTP, and laminin significantly correlated with the myocardial area fractions of their tissue analogues (PIIINP vs myocardial collagen type III, r = 0.784, p = 0.0013; serum ICTP vs myocardial collagen type I, r = 0.603, p = 0.0527; and serum laminin vs myocardial laminin, r = 0.605, p = 0.0411). In conclusion, the increase in extracellular matrix turnover, which may partially be derived from fibrosis in the myocardium, can be measured in the serum of patients with dilated cardiomyopathy, and has an impact on risk stratification and prognosis.

References (26)

ShiraniJ et al.
Usefulness of the electrocardiogram and echocardiogram in predicting the amount of interstitial myocardial collagen in endomyocardial biopsy specimens of patients with chronic heart failure
Am J Cardiol
(1992)
TrinchetJC et al.
Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis: relationship to liver histology and conventional liver tests
J Hepatol
(1991)
BishopJE et al.
Enhanced deposition of predominantly type I collagen in myocardial diseases
J Mol Cell Cardiol
(1990)
FigullaHR et al.
Spontaneous hemodynamic improvement or stabilization and associated biopsy findings in patients with congestive cardiomyopathy
Circulation
(1985)
PicanoE et al.
In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans
Circulation
(1990)
SchaperJ et al.
The extracellular matrix in the human failing heart
Basic Res Cardiol
(1992)
SchaperJ et al.
Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy
Circulation
(1991)
GramJ et al.
Increased serum concentration of type-I procollagen C-terminal propeptide and osteocalcin during short course of calcitriol administration to adult male volunteers
Acta Endocrinol
(1991)
Hørslev-PetersenK et al.
Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders
Clin Rheumatol
(1988)
HeikinheimoM et al.
N-terminal propeptide of type-III collagen in tracheal fluid and serum in preterm infants at risk for bronchopulmonary dysplasia
Pediatr Res
(1992)

CantinAM et al.

Increased procollagen III aminoterminal peptide-related antigens and fibroblast growth signals in the lung of patients with idiopathic pulmonary fibrosis

Am Rev Respir Dis

(1988)

PohlWR et al.

Serum procollagen III peptide levels in subjects with sarcoidosis

Am Rev Respir Dis

(1992)

EntzianP et al.

Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients. Pronounced augmented concentrations in the adult respiratory distress syndrome

Am Rev Respir Dis

(1990)

Cited by (233)

Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies
2023, Molecular Aspects of Medicine
Heart failure is a leading cause of mortality and hospitalization worldwide. Cardiac fibrosis, resulting from the excessive deposition of collagen fibers, is a common feature across the spectrum of conditions converging in heart failure. Eventually, either reparative or reactive in nature, in the long-term cardiac fibrosis contributes to heart failure development and progression and is associated with poor clinical outcomes. Despite this, specific cardiac antifibrotic therapies are lacking, making cardiac fibrosis an urgent unmet medical need. In this context, a better patient phenotyping is needed to characterize the heterogenous features of cardiac fibrosis to advance toward its personalized management. In this review, we will describe the different phenotypes associated with cardiac fibrosis in heart failure and we will focus on the potential usefulness of imaging techniques and circulating biomarkers for the non-invasive characterization and phenotyping of this condition and for tracking its clinical impact. We will also recapitulate the cardiac antifibrotic effects of existing heart failure and non-heart failure drugs and we will discuss potential strategies under preclinical development targeting the activation of cardiac fibroblasts at different levels, as well as targeting additional extracardiac processes.
Chimeric galectin-3 and collagens: Biomarkers and potential therapeutic targets in fibroproliferative diseases
2022, Journal of Biological Chemistry
Fibrosis, stiffening and scarring of an organ/tissue due to genetic abnormalities, environmental factors, infection, and/or injury, is responsible for > 40% of all deaths in the industrialized world, and to date, there is no cure for it despite extensive research and numerous clinical trials. Several biomarkers have been identified, but no effective therapeutic targets are available. Human galectin-3 is a chimeric gene product formed by the fusion of the internal domain of the collagen alpha gene [N-terminal domain (ND)] at the 5′-end of galectin-1 [C-terminal domain (CRD)] that appeared during evolution together with vertebrates. Due to the overlapping structural similarities between collagen and galectin-3 and their shared susceptibility to cleavage by matrix metalloproteases to generate circulating collagen-like peptides, this review will discuss present knowledge on the role of collagen and galectin-3 as biomarkers of fibrosis. We will also highlight the need for transformative approaches targeting both the ND and CRD domains of galectin-3, since glycoconjugate binding by the CRD is triggered by ND-mediated oligomerization and the therapies targeted only at the CRD have so far achieved limited success.
Myocardial fibrosis: morphologic patterns and role of imaging in diagnosis and prognostication
2022, Cardiovascular Pathology
Myocardial fibrosis is defined as an increased amount of collagen in the myocardium relative to cardiac myocytes. Two main morphologic patterns are recognized: 1) replacement fibrosis, which occurs in response to myocyte necrosis (myocardial scarring); and 2) interstitial fibrosis, which is usually a diffuse process and has been shown to be reversible and treatable. Replacement and interstitial fibrosis often coexist and are a constant feature of pathologic cardiac remodeling. In the last twenty years, there has been significant interest in developing objective non-invasive methods to identify and quantitatively assess myocardial fibrosis in vivo, both for diagnostic purposes and to improve stratification of patients.
The present Review focuses on the morphologic patterns of myocardial fibrosis observed either at autopsy and heart transplant, or in vivo by non-invasive imaging techniques. Main aim is to provide clues for the differential diagnosis, with emphasis on entities whose diagnosis may be challenging. An update on the diagnostic and prognostic role of imaging, along with recent data on available biomarkers, is also proposed.
Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms
2021, Biomedicine and Pharmacotherapy
Cardiovascular diseases are one of the leading causes of death worldwide and cardiac fibrosis is a common pathological process for cardiac remodeling in cardiovascular diseases. Cardiac fibrosis not only accelerates the deterioration progress of diseases but also becomes a pivotal contributor for futile treatment in clinical cardiovascular trials. Although cardiac fibrosis is common and prevalent, effective medicines to provide sufficient clinical intervention for cardiac fibrosis are still unavailable. Traditional Chinese medicine (TCM) is the natural essence experienced boiling, fry, and other processing methods, including active ingredients, extracts, and herbal formulas, which have been applied to treat human diseases for a long history. Recently, research has increasingly focused on the great potential of TCM for the prevention and treatment of cardiac fibrosis. Here, we aim to clarify the identified pro-fibrotic mechanisms and intensively summarize the application of TCM in improving cardiac fibrosis by working on these mechanisms. Through comprehensively analyzing, TCM mainly regulates the following pathways during ameliorating cardiac fibrosis: attenuation of inflammation and oxidative stress, inhibition of cardiac fibroblasts activation, reduction of extracellular matrix accumulation, modulation of the renin-angiotensin-aldosterone system, modulation of autophagy, regulation of metabolic-dependent mechanisms, and targeting microRNAs. We also discussed the deficiencies and the development direction of anti-fibrotic therapies on cardiac fibrosis. The data reviewed here demonstrates that TCM shows a robust effect on alleviating cardiac fibrosis, which provides us a rich source of new drugs or drug candidates. Besides, we also hope this review may give some enlightenment for treating cardiac fibrosis in clinical practice.
Quantification of diffuse myocardial fibrosis using CMR extracellular volume fraction and serum biomarkers of collagen turnover with histologic quantification as standard of reference
2021, Diagnostic and Interventional Imaging
Citation Excerpt :
The cardiac expression of TIMP-1 and TIMP-2 is significantly increased in chronic pressure-overloaded cardiopathy compared with controls and is related to the degree of interstitial fibrosis [7]. Nevertheless, propeptide of procollagen that correlates with histologic CVF [9,10], correlates with excentric and concentric cardiac remodeling in our study. Myocardial fibrosis increases ventricular stiffness and leads to diastolic dysfunction.
To compare the assessment of diffuse interstitial myocardial fibrosis in valvular diseases using cardiac magnetic resonance (CMR) extracellular volume fraction (ECV) quantification and serum biomarkers of collagen turnover using results of myocardial biopsy as standard of reference.
This prospective monocentric study included consecutive patients before aortic valvular replacement. All patients underwent: i), 1.5 T CMR with pre and post contrast T₁ mapping sequence and ECV computation; ii), serum quantification of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) and iii), myocardial biopsies were collected during surgery to assess collagen volume fraction (CVF). Patients with coronary artery disease were excluded. Correlation between native T1, ECV, CVF and serum biomarkers were assessed using Pearson correlation test. Agreement between basal anteroseptal ECV with global ECV was assessed using Bland-Altman test.
Twenty-one patients, 16 with aortic stenosis and 5 with aortic regurgitation were included. There were 12 men and 9 women with a mean age of 74.1 ± 6.8 (SD) years (range: 32–84 years). Mean global ECV value was 26.7 ± 2.7 (SD) % (range: 23.4–32.5%) and mean CVF value was 12.4 ± 9.7% (range: 3.2–25.7%). ECV assessed at the basal anteroseptal segment correlated moderately with CVF (r = 0.6; P = 0.0026). There was a strong correlation and agreement between basal anteroseptal ECV and global ECV, (r = 0.8; P < 0.0001; bias 5.4 ± 6.1%) but no correlation between global ECV and CVF (r = 0.5; P = 0.10). Global ECV poorly correlated with serum TIMP-1 (r = 0.4; P = 0.037) and MMP-2 (r = 0.4; P = 0.047). No correlation was found between serum biomarkers and basal anteroseptal- ECV or native T1.
In patients with severe aortic valvulopathy, diffuse myocardial fibrosis assessed by anterosepto-basal ECV correlates with histological myocardial fibrosis. Anteroseptobasal ECV strongly correlates with global ECV, which poorly correlates with TIMP-1 and MMP-2, serum biomarkers involved in the progression of heart failure.
Advances in bone turnover markers
2021, Advances in Clinical Chemistry
Bone fragility fractures remain an important worldwide health and economic problem due to increased morbidity and mortality. The current methods for predicting fractures are largely based on the measurement of bone mineral density and the utilization of mathematical risk calculators based on clinical risk factors for bone fragility. Despite these approaches, many bone fractures remain undiagnosed. Therefore, current research is focused on the identification of new factors such as bone turnover markers (BTM) for risk calculation. BTM are a group of proteins and peptides released during bone remodeling that can be found in serum or urine. They derive from bone resorptive and formative processes mediated by osteoclasts and osteoblasts, respectively. Potential use of BTM in monitoring these phenomenon and therefore bone fracture risk is limited by physiologic and pathophysiologic factors that influence BTM. These limitations in predicting fractures explain why their inclusion in clinical guidelines remains limited despite the large number of studies examining BTM.

View all citing articles on Scopus

: This study was supported mainly by Grant 9357-MED from the Fonds zur Fo¨rderung der wissenschaftlichen Forschung, and in part by Grant 4432 from the Anton-Dreher-Geda¨chtnisschenkung and Grant 193/ 91 from the Jubila¨umsfonds derO¨sterreichischen Nationalbank, Vienna, Austria.

View full text

Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis

Am J Cardiol

J Hepatol

J Mol Cell Cardiol

Spontaneous hemodynamic improvement or stabilization and associated biopsy findings in patients with congestive cardiomyopathy

Circulation

In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans

Circulation

The extracellular matrix in the human failing heart

Basic Res Cardiol

Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy

Circulation

Increased serum concentration of type-I procollagen C-terminal propeptide and osteocalcin during short course of calcitriol administration to adult male volunteers

Acta Endocrinol

Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders

Clin Rheumatol

N-terminal propeptide of type-III collagen in tracheal fluid and serum in preterm infants at risk for bronchopulmonary dysplasia

Pediatr Res

Increased procollagen III aminoterminal peptide-related antigens and fibroblast growth signals in the lung of patients with idiopathic pulmonary fibrosis

Am Rev Respir Dis

Serum procollagen III peptide levels in subjects with sarcoidosis

Am Rev Respir Dis

Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients. Pronounced augmented concentrations in the adult respiratory distress syndrome

Am Rev Respir Dis